135 related articles for article (PubMed ID: 34158961)
1. Pembrolizumab dramatically resolves choroidal metastatis from esophageal adenocarcinoma and restores vision: a case report.
Barrett D; Sumnicht A; Chalam KV; Rauser M
Oxf Med Case Reports; 2021 Jun; 2021(6):omab047. PubMed ID: 34158961
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S; Kato K
Expert Opin Biol Ther; 2020 Oct; 20(10):1143-1150. PubMed ID: 32620063
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.
Hu J; Ye Z; Xu Z; Hao Z; Wang Y
Front Public Health; 2022; 10():941738. PubMed ID: 36568792
[TBL] [Abstract][Full Text] [Related]
4. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
Shah MA; Kojima T; Hochhauser D; Enzinger P; Raimbourg J; Hollebecque A; Lordick F; Kim SB; Tajika M; Kim HT; Lockhart AC; Arkenau HT; El-Hajbi F; Gupta M; Pfeiffer P; Liu Q; Lunceford J; Kang SP; Bhagia P; Kato K
JAMA Oncol; 2019 Apr; 5(4):546-550. PubMed ID: 30570649
[TBL] [Abstract][Full Text] [Related]
6. A rare presentation of choroidal metastasis from primary esophageal adenocarcinoma successfully treated with intensity-modulated radiation therapy.
Date RC; Adams MK; Teh BS; Schefler AC; Musher BL; Farach A; Weng CY
Am J Ophthalmol Case Rep; 2018 Sep; 11():19-22. PubMed ID: 30057967
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
[TBL] [Abstract][Full Text] [Related]
8. Dynamic changes in pathology and PD-L1 expression in a patient with metastatic lung adenocarcinoma who received pembrolizumab therapy followed by two salvage surgeries two years later: A case report.
Hong G; Park HS; Yeo MK; Lee D; Chung C
Thorac Cancer; 2023 Aug; 14(23):2320-2324. PubMed ID: 37416998
[TBL] [Abstract][Full Text] [Related]
9. T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.
Shah MA; Kojima T; Hochhauser D; Enzinger P; Raimbourg J; Hollebecque A; Lordick F; Kim SB; Tajika M; Lockhart AC; Arkenau HT; El-Hajbi F; Gupta M; Pfeiffer P; Bhagia P; Cao ZA; Lunceford J; Suryawanshi S; Ayers M; J Marton M; Kato K
Future Oncol; 2022 Jul; ():. PubMed ID: 35852104
[No Abstract] [Full Text] [Related]
10. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
13. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J
J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900
[TBL] [Abstract][Full Text] [Related]
14. Vision loss with pembrolizumab treatment: A report of two cases.
Telfah M; Whittaker TJ; C Doolittle G
J Oncol Pharm Pract; 2019 Sep; 25(6):1540-1546. PubMed ID: 30997872
[TBL] [Abstract][Full Text] [Related]
15. Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook.
Jin Z; Shen J; Wang C; Chen D; Zhang B; Zhang J; Ajani JA; Bennouna J; Chao J; Yoon HH; Zhu H; Ruan Y; Zhu C; Xu A
Ann Transl Med; 2021 Jul; 9(14):1189. PubMed ID: 34430630
[TBL] [Abstract][Full Text] [Related]
16. Association of the programmed death ligand-1 combined positive score in tumors and clinicopathological features in esophageal cancer.
Huang Z; Jin Y; Cai X; Chen L; Shen X; Li B; Chen H; Li Y
Thorac Cancer; 2022 Feb; 13(4):523-532. PubMed ID: 34953041
[TBL] [Abstract][Full Text] [Related]
17. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.
Chen P; Yu M; Zhang JL; Chen WY; Zhu L; Song Y; Jiang CY; Zhang S
World J Clin Cases; 2020 Jul; 8(13):2876-2884. PubMed ID: 32742998
[TBL] [Abstract][Full Text] [Related]
18. Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Liang J; Li M; Sui Q; Hu Z; Bian Y; Huang Y; Zhan C; Jiang W; Wang Q; Tan L
Transl Lung Cancer Res; 2020 Aug; 9(4):1302-1323. PubMed ID: 32953506
[TBL] [Abstract][Full Text] [Related]
19. Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report.
Sato S; Senmaru N; Ishido K; Saito T; Poudel S; Muto J; Syouji Y; Hase R; Hirano S
Surg Case Rep; 2019 Oct; 5(1):166. PubMed ID: 31667679
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z
Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
